Myeloma News and Research

RSS

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Study shows critical role of immune system in protecting against viruses and cancer cells

A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.

9 Apr 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

EKF Molecular to exhibit PointMan DNA-enrichment technology at AACR 2014

EKF Diagnostics, the global in vitro diagnostics business, will be present on Booth #438 at AACR 2014, 5-9th April, San Diego.

From EKF Diagnostics 26 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Researchers have found that people born with a rare abnormality of their chromosomes have a 2,700-fold increased risk of a rare childhood leukaemia. In this abnormality, two specific chromosomes are fused together but become prone to catastrophic shattering.

24 Mar 2014

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells.

7 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

28 Feb 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies.

26 Feb 2014

Study: Blacks are more likely to have precursor condition than whites

Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance (MGUS), a Mayo Clinic study has found.

25 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

17 Feb 2014

Congressmen to receive Edwin C. Whitehead award at Advocacy Awards Dinner

Reps. Frank Wolf (R-VA) and Chaka Fattah (D-PA) will receive the Edwin C. Whitehead Award for Medical Research Advocacy for their leadership and unwavering commitment to supporting policies that promote federal and private sector medical research and innovation.

13 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.